Management of Diabetes Mellitus Patients With Retinopathy

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00828425
First received: January 23, 2009
Last updated: August 17, 2010
Last verified: August 2010

January 23, 2009
August 17, 2010
December 2008
Not Provided
  • Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
  • evolution of diabetic retinopathy [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00828425 on ClinicalTrials.gov Archive Site
concomitant medication [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Management of Diabetes Mellitus Patients With Retinopathy
Management of Diabetes Mellitus Patients With Retinopathy

Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed:

  • which medication are used to keep blood pressure under control?
  • which medication are used for metabolic control?
  • the average control level of metabolism and blood pressure is compliant with the international guidelines?
  • laser photocoagulation plays a role in the control of metabolism and blood pressure?
  • there are differences in the control of metabolism and blood pressure between patients with DM I or DM II?
  • there is an influence of renal failure on the choose of medication?
Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Diabetic patients with diabetic retinopathy

  • Retinopathy
  • Diabetes Mellitus
Not Provided
1
Diabetic patients with retinopathy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2500
August 2009
Not Provided

Inclusion Criteria:

  • Diabetic patients
  • Diabetic retinopathy
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00828425
NIS-CCH-DUM-2008/1
No
Dr. Med. Dirk Schneider - Medical Director, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Not Provided
AstraZeneca
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP